Goals of COPD treatment

The main goals of COPD treatment are to reduce symptoms and the risk of future exacerbations.1

These goals are defined in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 Strategy Report1

The management strategy for stable COPD should be based on the individualised assessment of symptoms and future risk of exacerbations.1

The main GOLD 2017 COPD treatment goals1

The main GOLD 2017 COPD treatment goals
The main GOLD 2017 COPD treatment goals

SPIOLTO® RESPIMAT® shows improvements beyond SPIRIVA® in major COPD endpoints

In clinical trials with >16,000 patients, SPIOLTO® RESPIMAT® (tiotropium/olodaterol) was consistently superior to its monotherapies and placebo, with significant improvements in major components of COPD.2,3 Clinical improvements compared with SPIRIVA® monotherapy were seen in overall COPD patients but were most apparent at the start of maintenance therapy (GOLD 2 patients).2-5








  1. Gold COPD strategy report 2017. Available at:
    [Accessed August 2017].
  2. Buhl R, et al. Eur Respir J. 2015;45:969-979.
  3. Singh D, et al. Respir Med. 2015;109:1312-1319.
  4. Ferguson GT, et al. Adv Ther 2015; 32: 523–536; Ferguson GT, et al. Adv Ther 2015; 32: 523–536 (supplementary material).
  5. Singh D et al Resp Res 2016;17(73):1-13 and supplementary information.